IMMUNE NETWORK

  • 제1권3호
  • /
  • Pages.260-265
  • /
  • 2001
  • /
  • 1598-2629(pISSN)
  • /
  • 2092-6685(eISSN)
대한면역학회 (The Korean Association of Immunobiologists)
권호 표지

위암 및 전립선암의 종양 표지 인자로서 혈장 TGF-β1에 대한 연구

Study of plasma TGF-β1 level as a useful tumor marker in gastric cancer and prostate cancer

  • 임창기 (한미약품 중앙연구소) ;
  • 신훈 (한미약품 중앙연구소) ;
  • 최인영 (한미약품 중앙연구소) ;
  • 정병하 (연세대학교 의과대학 세브란스병원 비뇨기과) ;
  • 류민희 (서울대학교 의과대학 혈액종양내과) ;
  • 방영주 (서울대학교 의과대학 혈액종양내과) ;
  • 진승원 (한미약품 중앙연구소)
  • Lim, Chang Ki (Central Research Institute, Hanmi Pharmaceutical Co., Ltd.) ;
  • Shin, Hoon (Central Research Institute, Hanmi Pharmaceutical Co., Ltd.) ;
  • Choi, In Young (Central Research Institute, Hanmi Pharmaceutical Co., Ltd.) ;
  • Chung, Byung Ha (Department of Urology, College of Medicine, Yonsei University) ;
  • Ryu, Min Hee (Department of Internal Medicine, College of Medicine, Seoul National University) ;
  • Bang, Yung Jue (Department of Internal Medicine, College of Medicine, Seoul National University) ;
  • Jin, Seung Won (Central Research Institute, Hanmi Pharmaceutical Co., Ltd.)
  • 발행 : 2001.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Transforming growth $factor-{\beta}1$ ($TGF-{\beta}1$) is a multipotent growth factor affecting development, homeostasis and tissue repair. Many kinds of malignant tissues were reported to overexpress transforming growth $factor-{\beta}1$ ($TGF-{\beta}1$) gene. However, a little work has been done on the circulating $TGF-{\beta}1$ and the association of $TGF-{\beta}1$ with progression in patients with malignant tumors. In this study, we measured the plasma level of $TGF-{\beta}1$ in gastric cancer and prostate cancer patients and evaluated the utility of plasma $TGF-{\beta}1$ as a possible tumor marker. We used Enzyme-linked immunosorbent assay (ELISA) system in order to measure plasma $TGF-{\beta}1$ level in 134 gastric cancer patients, 50 prostate cancer patients and 290 normal controls. And the tumor marker, carcinoembryonic antigen (CEA), prostate-specific antigen (PSA), was compared with $TGF-{\beta}1$ in the aspects of sensitivity and specificity. The mean plasma $TGF-{\beta}1$ levels were $1.219{\pm}0.834$ (0.272-5.772) ng/mL in normal controls, $5.964{\pm}3.218$ (0.845-18.124) ng/mL in gastric cancer and $4.140{\pm}2.345$ (1.108-13.302) ng/mL in prostate cancer. In gastric cancer patients difference in plasma $TGF-{\beta}1$ level was not detected according to cancer stage. In comparison with other tumor marker (CEA, PSA) $TGF-{\beta}1$ is more potent in sensitivity. These results indicate that the plasma $TGF-{\beta}1$ level can be a potent tumor marker in gastric cancer and prostate cancer.

키워드